Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART

This study is ongoing, but not recruiting participants.
AIDS Research Consortium of Atlanta
University of Alabama at Birmingham
AIDS Research Alliance
Information provided by (Responsible Party):
GeoVax, Inc. Identifier:
First received: July 30, 2010
Last updated: May 23, 2013
Last verified: May 2013

GV-TH-01 is an open label Phase 1 study of 9 HIV-1 infected adults with suppressed viremia who started anti-retroviral therapy (ART) within 18 months of a negative HIV antibody test. This study has 3 phases. The first phase is the vaccination phase, where patients are vaccinated with pGA2/JS7 (JS7)DNA and MVA62B vaccines on a prime/boost regimen at weeks 1 and 9 (JS7 DNA vaccine) and weeks 17 and 25 (MVA62B). Both vaccines express Gag, Pol, and Env. The second phase of the study is a treatment interruption phase, whereby ART is interrupted for a 12 week period approximately 8 weeks following the last vaccination. The third phase occurs after the 12 week treatment interruption phase and is called the treatment reinstitution phase, because subjects reinstitute ART and are followed for an additional 24 weeks. The primary objective is to evaluate the safety of the vaccines during the three phases of the study. A secondary objective is to evaluate the immunogenicity of the vaccines during the vaccination phase of the study.

Condition Intervention Phase
HIV-1 Infection
Biological: JS7 plasmid DNA and MVA62B vaccine
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62B in HIV-infected Adults With Suppressed Viremia Who Started ART Within 18 Months of a Negative HIV Antibody Test

Resource links provided by NLM:

Further study details as provided by GeoVax, Inc.:

Primary Outcome Measures:
  • Safety in all phases of study. [ Time Frame: Throughout study - up to 77 weeks ] [ Designated as safety issue: Yes ]
    Frequency and severity of adverse events, laboratory abnormalities, and local and systemic reactogenicity signs and symptoms following vaccinations. Vaccination(virologic failure): HIV-1 RNA >200 copies/mL and CD4+ <350 cells/uL; genotypic resistance patterns of re-emergent virus. Treatment interruption:number(#)and percentage(%): 1)meet HIV-1 RNA and CD4+ criteria to re-institute anti-retroviral therapy before 12 wks; 2)genotypic resistance in re-emergent virus. Treatment reinstitution:# and %: 1)meet criteria for virologic failure; 2)genotypic resistance in patients with virologic failure.

Secondary Outcome Measures:
  • Immunogenicity [ Time Frame: Throughout vaccination and treatment interruption phases ] [ Designated as safety issue: No ]
    Magnitude of interferon (ifn) gamma &/or interleukin-2 (IL-2) producing CD4+ and CD8+ T cells at 1 week (wk) post 2nd MVA (modified vaccinia ankara) vaccination (vacc); titer & avidity index of binding aby for Env at 2 wks post 2nd MVA vacc. Magnitude of ifn-gamma &/or IL-2 producing CD4+ & CD8+ cells, # and id of Gag-specific CD8+ responses & titers of binding aby for Env at 2 wks post detection of re-emergent virus. Log change in HIV-1 RNA from before antiretroviral therapy to end of treatment interruption; time to HIV-1 rebound to >200 copies/mL.

Enrollment: 9
Study Start Date: June 2010
Estimated Study Completion Date: May 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: JS7 plasmid DNA and MVA62B vaccines
All subjects receive JS7 plasmid DNA (at 1 and 9 weeks) and MVA62B vaccines (17 and 25 weeks), followed (in 2 months after last vaccination) by a 12-week treatment interruption phase. Subjects reinstitute therapy after the treatment interruption and are followed for 6 months.
Biological: JS7 plasmid DNA and MVA62B vaccine
JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
Other Name: pGA2/JS7 and MVA/HIV62B vaccine


Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 through 50 years
  • Time between start of ART and last documented negative HIV antibody test within 18 months; or time from negative detuned HIV-1 antibody assay to start of ART within 13 months; or time between evolution of Western blot from indeterminate to positive (as defined by CDC/ASTPHLD) in the presence of a positive antibody test and initiation of ART is within 18 months
  • No changes to ART treatment within 4 weeks of study entry
  • Documentation of level of plasma HIV-1 RNA and CD4+ counts prior to beginning ART
  • On stable suppressive ART, defined as HIV-1 RNA < 50 copies/mL (PCR) or < 75 copies/mL (bDNA) for a minimum of 6 months prior to starting vaccination so that at least two measures must have occurred within the 6 months preceding vaccination (One may be from the chart and one at screening)
  • No history of virologic failure, failure defined as HIV-1 RNA > 50 copies/mL (PCR) or > 75 copies/mL (bDNA), after achieving suppression below those levels or failure to reach HIV-1 RNA < 50 copies/mL (PCR) or < 75 copies/mL (bDNA) on initial antiretroviral regimen (Substitutions due to intolerance are allowed)
  • CD4+ > 500 cells/µL
  • Nadir CD4+ > 350 cells/µL unless measured in the setting of acute infection
  • Laboratory values:

    • Hemoglobin ≥ 10g/dL (male) or 9g/dL (women)
    • ANC > 1000 cells/µL
    • ALT, AST ≤ 2.5 ULN
    • Total bilirubin < 1.5 x ULN (≤ 5 x ULN on atazanavir)
    • Fasting glucose ≤ 125 mg/dL
    • Serum creatine < 1.5 x ULN
    • Creatinine clearance ≥ 60 mL/min (Cockcroft-Gault)
    • Serum creatine phosphokinase (CPK) ≤ 1.5 x ULN
    • UA negative for hemoglobin and glucose and no greater than 1+ protein
    • Any abnormalities must be assessed by the investigator as not clinically significant
  • ECG without evidence of current or past MI, or ischemic heart disease
  • Willing to provide signed informed consent
  • Female subjects must have a negative serum or urine β-HCG pregnancy test at screening
  • Female subjects of reproductive potential (not having reached menopause or not having undergone hysterectomy, bilateral oophorectomy, or tubal ligation) who engage in sexual activity that could lead to pregnancy must agree to avoid pregnancy and agree to consistently use contraception for at least 21 days prior to first vaccination until the last protocol visit.
  • Contraception is defined as using at least one of the following methods:

    • Condoms (male or female)
    • Diaphragm or cervical cap
    • Intrauterine device (IUD)
    • Hormonal contraceptive with one of the following: condoms, diaphragm or cervical cap
  • Male subjects participating in the study must agree to not attempt to impregnate a female, or participate in sperm donation programs
  • Males engaging in sexual activity that could lead to pregnancy must use a condom from the date of receipt of the first study vaccine until the last protocol visit
  • Male and female subjects participating in the study must agree to use condoms for protection against HIV-1 transmission throughout the study
  • Participants must be willing to comply with all study requirements and expected to be available for the duration of the study
  • Participants must be willing to temporarily discontinue antiretroviral therapy for up to 12 weeks post-vaccinations

Exclusion Criteria:

  • Known infection with HIV-1 subtype other than Clade B
  • Receipt of chemotherapy for active malignancy in the past 12 months
  • Prior vaccinations with any HIV-1 vaccine
  • Prior vaccination against smallpox within the last 15 years
  • History of or known cardiac disease including:

    • myocardial infarction
    • angina pectoris
    • congestive heart failure
    • cardiomyopathy
    • pericarditis
    • stroke or transient ischemic attack
    • symptoms suggestive of cardiac disease in the opinion of the investigator
  • History of myositis
  • Diagnosis of HIV-associated nephropathy
  • Evidence of active hepatitis B or C infection, including positive HBsAG or positive hepatitis C antibody
  • Framingham Global Risk Assessment Score consistent with high short-term (10 year) cardiac risk
  • Receipt of immunomodulatory agents, systemic corticosteroids (including nonprescription street steroids), gamma globulin, or investigational agents (other than H1N1 influenza vaccine) within 6 months of screening
  • Any immunization within 1 month of screening and within 2 weeks of any inoculation in this study
  • Creatine supplements within 14 days of baseline and unwillingness to discontinue use throughout the trial
  • Changes in ART regimen prior to entry due to virologic failure (not including toxicity)
  • Pregnancy or breastfeeding
  • Any clinically significant diseases (other than HIV-1 infection) or clinically significant findings during the screening medical history or physical examination that, in the investigator's opinion, would compromise participant safety
  • Active alcohol or substance abuse, defined as use that is likely to interfere with the ability of the subject to adhere to medications, return for study visits or lead to adverse events
  • Allergy to chicken egg derived products
  • Contraindication to intramuscular injection such as anticoagulant therapy or thrombocytopenia
  • Unwilling to forego vigorous exercise 3 days prior to each vaccination
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01378156

United States, Alabama
The University of Alabama at Birmingham Alabama Vaccine Research Clinic
Birmingham, Alabama, United States, 35294
United States, California
AIDS Research Alliance
Los Angeles, California, United States, 90015
United States, Georgia
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States, 30312
Sponsors and Collaborators
GeoVax, Inc.
AIDS Research Consortium of Atlanta
University of Alabama at Birmingham
AIDS Research Alliance
Study Chair: Harriet L Robinson, PhD GeoVax, Inc.
  More Information

No publications provided

Responsible Party: GeoVax, Inc. Identifier: NCT01378156     History of Changes
Other Study ID Numbers: GV-TH-01
Study First Received: July 30, 2010
Last Updated: May 23, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by GeoVax, Inc.:
Therapy for HIV Infection
Suppressive ART with no failures
Treatment interruption

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases processed this record on February 25, 2015